Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

被引：0

作者：

Piedra, A. ^{[1
]}

Barba Joaquin, A. ^{[1
]}

Mosquera Martinez, J. ^{[2
]}

Fernandez Bruno, M. ^{[2
]}

Cordeiro Gonzalez, P. ^{[3
]}

Sullivan, I. G. ^{[1
]}

Riudavets Melia, M. ^{[1
]}

Aguado Sorolla, M. ^{[1
]}

Gallardo Melo, P. ^{[1
]}

Martin Cullell, B. ^{[4
]}

Gavira, J. ^{[1
]}

Tapia, J. C. ^{[1
]}

Romano, A. ^{[1
]}

Bosma, F. ^{[5
]}

Sanchez Del Rio, S. ^{[1
]}

Sanz Beltran, J. ^{[1
]}

Molina Perez, M. A. ^{[6
]}

Serra Lopez, J. ^{[1
]}

Garcia Campelo, M. R. ^{[7
]}

Majem Tarruella, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[2] CHUAC Complexo Hosp Univ A Coruna, Med Oncol Serv Dept, La Coruna, Spain

[3] CHUAC Complexo Hosp Univ A Coruna, Oncol Dept, La Coruna, Spain

[4] Hosp Santa Creu & Sant Pau, Dept Oncol, Barcelona, Spain

[5] Hosp Santa Creu & Sant Pau, Oncol, Barcelona, Spain

[6] Hosp Santa Creu & Sant Pau, Oncol Med, Barcelona, Spain

[7] Inst Invest Biomed A Coruna INIBIC, Dept Med Oncol, La Coruna, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1098P

引用

页码：S1053 / S1053

页数：1

共 50 条

[31] Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
Barba Joaquin, A.
Mosquera, J.
Riudavets Melia, M.
Gomez-Randulfe, M. I.
Garcia Campelo, M. R.
Sullivan, I.
Serra Lopez, J.
Aguado, M.
Piedra, A.
Majem, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1081 - S1081
[32] PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006
Carlino, M.
Emancipator, K.
Ibrahim, N.
Zhou, H.
Schadendorf, D.
Ribas, A.
Gonzalez, R.
Hoeller, C.
Bar-Sela, G.
Barrow, C.
Chao, D.
Wolter, P.
Berking, C.
Straume, O.
Berrocal, A.
Holgado, E.
Gangadhar, T. C.
Weiss, G.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 44 - 44
[33] Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
Aguiar, Pedro Nazareth
Tadokoro, Hakaru
Barreto, Carmelia Maria Noia
Santoro, Ilka Lopes
De Mello, Ramon Andrade
Babiker, Hani M.
Avancha, Kiran
Lopes, Gilberto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Takumida, Hiroshi
Horinouchi, Hidehito
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru
Ohe, Yuichiro
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 737 - 746
[35] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Hiroshi Takumida
Hidehito Horinouchi
Ken Masuda
Yuki Shinno
Yusuke Okuma
Tatsuya Yoshida
Yasushi Goto
Noboru Yamamoto
Yuichiro Ohe
Cancer Immunology, Immunotherapy, 2022, 71 : 737 - 746
[36] Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
Llop Serna, S.
Puig, E.
Palmero, R.
Brenes, J.
Vilarino, N.
Ruffinelli, J. C. C.
Mesia Barroso, C.
Saldana Canada, J.
Jove Casulleras, M.
Brao Perez, I.
Arellano, M.
Luciano Mateo, F. N.
Peiro Martinez, I.
Munoz Pinedo, C.
Nadal, E.
ANNALS OF ONCOLOGY, 2021, 32 : S1012 - S1012
[37] Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
Ding, Kaiyue
Yi, Minhan
Liang, Hui
Li, Zhongkui
Zhang, Yuan
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (07) : 759 - 771
[38] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Incorvaia, Lorena
Fanale, Daniele
Badalamenti, Giuseppe
Barraco, Nadia
Bono, Marco
Corsini, Lidia Rita
Galvano, Antonio
Gristina, Valerio
Listi, Angela
Vieni, Salvatore
Gori, Stefania
Bazan, Viviana
Russo, Antonio
ADVANCES IN THERAPY, 2019, 36 (10) : 2600 - 2617
[39] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia
Daniele Fanale
Giuseppe Badalamenti
Nadia Barraco
Marco Bono
Lidia Rita Corsini
Antonio Galvano
Valerio Gristina
Angela Listì
Salvatore Vieni
Stefania Gori
Viviana Bazan
Antonio Russo
Advances in Therapy, 2019, 36 : 2600 - 2617
[40] Association between very high PD-l1 expression versus high PD-l1 expression in patients receiving pembrolizumab as firstline treatment for advanced non-small cell lung cancer
Shah, Syed Mohsin Mahmood
Marmarelis, Melina
Mamtani, Ronac
Hubbard, Rebecca
Hennessy, Sean
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 96 - 97

← 1 2 3 4 5 →